The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Global challenges and policy solutions in breast cancer control
Open accessAbstract
Breast cancer is the leading cause of cancer morbidity, disability and mortality in women, worldwide. Overall, in 2020, it was the most diagnosed malignancy. Differences in breast cancer mortality have been historically evidenced, as a result of disparities in access to diagnosis, treatment and palliative care. Epidemiologic trends in the last decades display three main patterns of breast cancer mortality: some high-income countries report continuous substantial improvements exceeding 2% annual mortality reduction; however, many low- and middle-income countries (LMICs) have stagnant or even increasing mortality rates. Population-based studies show that investing in breast cancer control, based on a primary health care approach, and expanding the cancer treatment capacity can portend population health benefits, with positive changes of the epidemiological adverse trajectories. Framed as part of the political commitment to the Sustainable Development Goals Agenda, World Health Organization (WHO) has recently launched a global initiative to tackle disparities in breast cancer mortality. The WHO-led Global Breast Cancer Initiative (GBCI) is framed across 3 pillars, to address key determinants of the cancer-related outcomes: health promotion and early detection, timely access to diagnosis and treatment, comprehensive breast cancer treatment, palliative and survivorship care. GBCI is a systematized approach, with the goal to (i) increase the fraction of newly diagnosed invasive cancers being stage 1 or 2 at diagnosis (60% or more), (ii) ensure diagnostic work-up to be completed within 60 days from the first connection with the primary healthcare providers to avoid delays in diagnosis and treatment and (iii) assure 80% or more women with breast cancer to undergo and complete multimodal treatments. GBCI will pursue a comprehensive and multisectoral approach, to deliver population health, social and economic benefits, ultimately intended as an entry point for health system strengthening and for the broader cancer control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Vos, T., Lim, S. S., Abbafati, C., Abbas, K. M., Abbasi, M., Abbasifard, M., Abbasi-Kangevari, M., Abbastabar, H., Abd-Allah, F., Abdelalim, A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30925-9 · Cited by 19,358
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Nikšić, M., Bonaventure, A., Valkov, M., Johnson, C. J., Estève, J., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33326-3 · Cited by 6,145
Maringe, C., Spicer, J., Morris, M., Purushotham, A., Nolte, E., Sullivan, R., Rachet, B., & Aggarwal, A. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30388-0 · Cited by 1,807
Influence of delay on survival in patients with breast cancer: a systematic review
Richards, M., Westcombe, A., Love, S., Littlejohns, P., & Ramirez, A. (1999) · The Lancet · doi:10.1016/s0140-6736(99)02143-1 · Cited by 1,171
The global burden of women's cancers: a grand challenge in global health
Ginsburg, O., Bray, F., Coleman, M. P., Vanderpuye, V., Eniu, A., Kotha, S. R., Sarker, M., Huong, T. T., Allemani, C., Dvaladze, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)31392-7 · Cited by 1,127
Self-citationBreast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis
Forouzanfar, M. H., Foreman, K. J., Delossantos, A. M., Lozano, R., Lopez, A. D., Murray, C. J. L., & Naghavi, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)61351-2 · Cited by 1,009
International Variation in Female Breast Cancer Incidence and Mortality Rates
DeSantis, C. E., Bray, F., Ferlay, J., Lortet-Tieulent, J., Anderson, B. O., & Jemal, A. (2015) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-15-0535 · Cited by 804
Self-citationBreast cancer early detection: A phased approach to implementation
Ginsburg, O., Yip, C., Brooks, A., Cabanes, A., Caleffi, M., Dunstan Yataco, J. A., Gyawali, B., McCormack, V., McLaughlin de Anderson, M., Mehrotra, R., et al. (2020) · Cancer · doi:10.1002/cncr.32887 · Cited by 744
Self-citationDelays and Disruptions in Cancer Health Care Due to COVID-19 Pandemic: Systematic Review
Riera, R., Bagattini, Â. M., Pacheco, R. L., Pachito, D. V., Roitberg, F., & Ilbawi, A. (2021) · JCO Global Oncology · doi:10.1200/go.20.00639 · Cited by 499
Self-citationCancer Control in Low- and Middle-Income Countries: Is It Time to Consider Screening?
Shah, S. C., Kayamba, V., Peek, R. M., & Heimburger, D. (2019) · Journal of Global Oncology · doi:10.1200/jgo.18.00200 · Cited by 382
Plevritis, S. K., Munoz, D., Kurian, A. W., Stout, N. K., Alagoz, O., Near, A. M., Lee, S. J., van den Broek, J. J., Huang, X., Schechter, C. B., et al. (2018) · JAMA · doi:10.1001/jama.2017.19130 · Cited by 302
Anderson, B. O., Ilbawi, A. M., Fidarova, E., Weiderpass, E., Stevens, L., Abdel-Wahab, M., & Mikkelsen, B. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00071-1 · Cited by 293
Self-citationJoko‐Fru, W. Y., Miranda‐Filho, A., Soerjomataram, I., Egue, M., Akele‐Akpo, M., N'da, G., Assefa, M., Buziba, N., Korir, A., Kamate, B., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.32406 · Cited by 269
McCormack, V., McKenzie, F., Foerster, M., Zietsman, A., Galukande, M., Adisa, C., Anele, A., Parham, G., Pinder, L. F., Cubasch, H., et al. (2020) · The Lancet Global Health · doi:10.1016/s2214-109x(20)30261-8 · Cited by 234
Self-citationPopulation-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer
Engmann, N. J., Golmakani, M. K., Miglioretti, D. L., Sprague, B. L., Kerlikowske, K., & for the Breast Cancer Surveillance Consortium (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6326 · Cited by 223
Economic Benefits of Investing in Women’s Health: A Systematic Review
Onarheim, K. H., Iversen, J. H., & Bloom, D. E. (2016) · PLoS ONE · doi:10.1371/journal.pone.0150120 · Cited by 208
Duggan, C., Trapani, D., Ilbawi, A. M., Fidarova, E., Laversanne, M., Curigliano, G., Bray, F., & Anderson, B. O. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00462-9 · Cited by 208
Self-citationNational cancer control plans: a global analysis
Romero, Y., Trapani, D., Johnson, S., Tittenbrun, Z., Given, L., Hohman, K., Stevens, L., Torode, J. S., Boniol, M., & Ilbawi, A. M. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30681-8 · Cited by 199
Self-citationTamimi, R. M., Spiegelman, D., Smith-Warner, S. A., Wang, M., Pazaris, M., Willett, W. C., Eliassen, A. H., & Hunter, D. J. (2016) · American Journal of Epidemiology · doi:10.1093/aje/kww145 · Cited by 190
Fundytus, A., Sengar, M., Lombe, D., Hopman, W., Jalink, M., Gyawali, B., Trapani, D., Roitberg, F., De Vries, E. G. E., Moja, L., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00463-0 · Cited by 178
Self-citationBertram, M. Y., Sweeny, K., Lauer, J. A., Chisholm, D., Sheehan, P., Rasmussen, B., Upreti, S. R., Dixit, L. P., George, K., & Deane, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30665-2 · Cited by 175
Duggan, C. R., Dvaladze, A. L., Rositch, A. F., Ginsburg, O., Yip, C. H., Horton, S., Rodríguez, R. C., Eniu, A. E., Mutebi, M. C., Bourque, J., et al. (2020) · Cancer · doi:10.1002/cncr.32891 · Cited by 170
Self-citationHanly, P., Soerjomataram, I., & Sharp, L. (2015) · International Journal of Cancer · doi:10.1002/ijc.29105 · Cited by 169
Cao, B., Bray, F., Ilbawi, A., & Soerjomataram, I. (2018) · The Lancet Global Health · doi:10.1016/s2214-109x(18)30411-x · Cited by 169
Self-citationYadav, U. N., Rayamajhee, B., Mistry, S. K., Parsekar, S. S., & Mishra, S. K. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.00508 · Cited by 164
Comparison of essential medicines lists in 137 countries
Persaud, N., Jiang, M., Shaikh, R., Bali, A., Oronsaye, E., Woods, H., Drozdzal, G., Rajakulasingam, Y., Maraj, D., Wadhawan, S., et al. (2019) · Bulletin of the World Health Organization · doi:10.2471/blt.18.222448 · Cited by 137
Knaul, F. M., Bhadelia, A., Rodriguez, N. M., Arreola‐Ornelas, H., & Zimmermann, C. (2018) · The Lancet Global Health · doi:10.1016/s2214-109x(18)30082-2 · Cited by 132
Cherny, N. I., Sullivan, R. J., Torode, J., Saar, M., & Eniu, A. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx521 · Cited by 130
Hu, K., Ding, P., Wu, Y., Tian, W., Pan, T., & Zhang, S. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-028461 · Cited by 115
Xu, S., Liu, Y., Zhang, T., Zheng, J., Lin, W., Cai, J., Zou, J., Chen, Y., Xie, Y., Chen, Y., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.689562 · Cited by 112
Reframing non-communicable diseases as socially transmitted conditions
Allen, L. N., & Feigl, A. B. (2017) · The Lancet Global Health · doi:10.1016/s2214-109x(17)30200-0 · Cited by 80
Factors influencing diagnosis delay of advanced breast cancer in Moroccan women
Maghous, A., Rais, F., Ahid, S., Benhmidou, N., Bellahamou, K., Loughlimi, H., Marnouche, E., Elmajjaoui, S., Elkacemi, H., Kebdani, T., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2394-y · Cited by 77
Breast Cancer Disparities Among Women in Low- and Middle-Income Countries
Ginsburg, O., Rositch, A. F., Conteh, L., Mutebi, M. C., Paskett, E. D., & Subramanian, S. (2018) · Current Breast Cancer Reports · doi:10.1007/s12609-018-0286-7 · Cited by 55
Self-citationWait, S., Han, D., Muthu, V., Oliver, K. R., Chrostowski, S., Florindi, F., Lorenzo, F. D., Gandouet, B., Spurrier‐Bernard, G., Ryll, B., et al. (2017) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2017.05.004 · Cited by 49
Cancer medicines in Asia and Asia-Pacific: What is available, and is it effective enough?
Eniu, A. E., Cherny, N. I., Bertram, M., Thongprasert, S., Douillard, J.-Y., Bricalli, G., Vyas, M., & Trapani, D. (2019) · ESMO Open · doi:10.1136/esmoopen-2018-000483 · Cited by 48
Self-citationProductivity Costs Associated With Breast Cancer Among Survivors Aged 18–44 Years
Ekwueme, D. U., Trogdon, J. G., Khavjou, O., & Guy, G. P. (2016) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2015.10.006 · Cited by 45
Assessment of Breast Cancer Management in Sub-Saharan Africa
Vanderpuye, V. D. N. K., Dadzie, M.-A., Huo, D., & Olopade, O. I. (2021) · JCO Global Oncology · doi:10.1200/go.21.00282 · Cited by 44
COVID-19 pandemic and health-care disruptions: count the most vulnerable
Kumar, J., & Kumar, P. M. (2021) · The Lancet Global Health · doi:10.1016/s2214-109x(21)00098-x · Cited by 43
Love, S. M., Berg, W. A., Podilchuk, C. I., Aldrete, A. L. L., Mascareño, A. P. G., Pathicherikollamparambil, K., Sankarasubramanian, A., Eshraghi, L., & Mammone, R. J. (2018) · Journal of Global Oncology · doi:10.1200/jgo.17.00222 · Cited by 42
Vranken, M. J. M., Lisman, J. A., Mantel-Teeuwisse, A. K., Jünger, S., Scholten, W. K., Radbruch, L., Payne, S. A., & Schutjens, M.-H. D. B. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00365-4 · Cited by 36
Long-Term Economic and Employment Outcomes Among Partners of Women With Early-Stage Breast Cancer
Veenstra, C. M., Wallner, L. P., Jagsi, R., Abrahamse, P. H., Griggs, J. J., Bradley, C. J., & Hawley, S. T. (2017) · Journal of Oncology Practice · doi:10.1200/jop.2017.023606 · Cited by 33
Productivity costs associated with metastatic breast cancer in younger, midlife, and older women
Trogdon, J. G., Liu, X., Reeder‐Hayes, K. E., Rotter, J., Ekwueme, D. U., & Wheeler, S. B. (2020) · Cancer · doi:10.1002/cncr.33077 · Cited by 30
Economic Evaluations of Breast Cancer Care in Low- and Middle-Income Countries: A Scoping Review
Erfani, P., Bhangdia, K. P., Stauber, C. E., Mugunga, J. C., Pace, L. E., & Fadelu, T. A. (2021) · The Oncologist · doi:10.1002/onco.13841 · Cited by 28
Self-citationOn the need for integrating cancer into the One Health perspective
Dujon, A. M., Brown, J. S., Destoumieux‐Garzón, D., Vittecoq, M., Hamede, R., Tasiemski, A., Boutry, J., Tissot, S., Alix‐Panabières, C., Pujol, P., et al. (2021) · Evolutionary Applications · doi:10.1111/eva.13303 · Cited by 28
The Global Macroeconomic Burden of Breast Cancer: Implications for Oncologic Surgery.
Ranganathan, K. L., Singh, P., Raghavendran, K., Wilkins, E. G., Hamill, J. B., Aliu, O., Newman, L. A., Hutton, D. W., & Momoh, A. O. (2021) · PubMed · doi:10.1097/sla.0000000000003662 · Cited by 27
The Global Landscape of Treatment Standards for Breast Cancer
Trapani, D., Douillard, J.-Y., Winer, E. P., Burstein, H. J., Carey, L., Cortés, J., Junior, G. L. L., Gralow, J. R., Gradishar, W. J., Magrini, N., et al. (2021) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djab011 · Cited by 22
Self-citationWhy Oncologists Should Care About Climate Change
Schiller, J. H., Averbuch, S. D., & Berg, C. D. (2020) · JCO Oncology Practice · doi:10.1200/op.20.00609 · Cited by 17
How can biosimilars change the trajectory of breast cancer therapy?
Trapani, D., & Curigliano, G. (2020) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2020.1757438 · Cited by 13
Self-citation
Research works printed but not linked: 7
- Mandelblatt, 2011, Modeling the impact of population screening on breast cancer mortality in the United States, The Breast, 20, S75, 10.1016/S0960-9776(11)70299-5 · doi:10.1016/s0960-9776(11)70299-5
- Qu, 2020, Interventions Addressing Barriers to Delayed Cancer Diagnosis in Low- and Middle-Income Countries: A Systematic Review, Oncologist, 25, e1382, 10.1634/theoncologist.2019-0804 · doi:10.1634/theoncologist.2019-0804
- Trapani, 2021, The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2-positive breast cancer: The ONCOLLEGE-001 survey, J Cancer Policy, 28, 100285, 10.1016/j.jcpo.2021.100285 · doi:10.1016/j.jcpo.2021.100285
- Trapani, 2020, Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems, Breast Care, 14, 373, 10.1159/000502637 · doi:10.1159/000502637
- Trapani, 2021, The global landscape of drug development of trastuzumab biosimilars, J Cancer Policy, 28, 100273, 10.1016/j.jcpo.2021.100273 · doi:10.1016/j.jcpo.2021.100273
- Global Governance Project. Health – A Political Choice: Solidary, Science and Solutions; 2021. Available at: https://edition.pagesuite-professional.co.uk/html5/reader/production/default.aspx?pubname=&edid=6928479a-6546-41b2-a749-c6bec78a3f08.
- Yamauchi H, Kitano A, Fukuda T. Socioeconomic impact of breast cancer survivors. Meeting of the American Society of Clinical Oncology 2014. #e20611. DOI: 10.1200/jco.2014.32.15_suppl.e20611 Journal of Clinical Oncology 32, no. 15_suppl. · doi:10.1200/jco.2014.32.15_suppl.e20611
Cited by
Zhang, H., Yue, X., Chen, Z., Liu, C., Wu, W., Zhang, N., Liu, Z., Yang, L., Jiang, Q., Cheng, Q., et al. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01860-5 · Cited by 424
Ji, Q.-L., Zeng, Y., Zhou, H., Wang, Q.-B., Zhou, R.-Y., Zhang, J.-J., & Wang, X. (2026) · Scientific reports · doi:10.1038/s41598-026-49617-6 · Cited by 1
Metadata
- Authors
- Trapani, D., Ginsburg, O., Fadelu, T., Lin, N. U., Hassett, M., Ilbawi, A. M., Anderson, B. O., & Curigliano, G.
- Venue
- Cancer Treatment Reviews
- Publisher
- Elsevier BV
- Published
- 2022-03
- Volume
- 104
- Pages
- 102339
- ISSN
- 0305-7372 (ISSN-L)
- OpenAlex
- W4206765651
- Cited by
- 316
- References
- 50
- FWCI
- 23.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- doi.org/10.15223/policy-017 (stm-asf)
- doi.org/10.15223/policy-037 (stm-asf)
- doi.org/10.15223/policy-012 (stm-asf)
- doi.org/10.15223/policy-029 (stm-asf)
- doi.org/10.15223/policy-004 (stm-asf)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.